Examples of Kite Product in a sentence
Notwithstanding the foregoing, Kite shall have the right, and it shall not be a breach of its foregoing exclusivity obligation, to Exploit a Bi-Specific Product directed against both (i) a Kite Target (but not an Amgen Target) and (ii) another Target which is not an Amgen Target, in which event such Bi-Specific Product, to the extent it contains a Kite Product, shall be deemed a Kite Product for all purposes, including financial provisions, under this Agreement.
On a Kite Target-by-Kite Target basis, Kite shall (directly and/or through one or more Affiliates and/or Sublicensees) use Commercially Reasonable Efforts to develop, and if successful, commercialize a Kite Product directed against such Kite Target.
On a Kite Target-by-Kite Target basis, until the Marketing Approval Milestone Payment set forth in Section 8.1.4 (Milestone Payments) has been made with respect to the first Kite Product directed against such Kite Target, on […***…], Kite shall submit to Amgen a report providing a status of Kite’s and its Affiliates’ and Sublicensees’ activities related to the Exploitation of Kite Products directed against such Kite Target during the preceding […***…].
On a Kite Target-by-Kite Target basis, at any time after the Initiation of the first Phase 1 Clinical Trial for the first Kite Product to such Kite Target, Kite will have the right to terminate this Agreement with respect to such Kite Target […***…] after delivery of written notice to Amgen thereof.
In the event that Kite does not elect to enforce any Patent Right within the Amgen Patents or Collaboration Patents, then Amgen shall be entitled to do so, unless Kite has a good faith belief that Amgen’s enforcement of such Patent Rights would be reasonably likely to jeopardize the Exploitation of a Kite Product.
For each Kite Target, Kite shall reimburse Amgen for any amounts paid by Amgen to Kite for Preclinical Development related to the applicable Program for such Kite Target, within […***…] after the filing of an IND for the first Kite Product under such Program, unless Amgen has elected to exercise the option set forth in Section 4.2 (Amgen Optioned Target) with respect to […***…].
On a Kite Target-by-Kite Target basis, at any time prior to the Initiation of the first Phase 1 Clinical Trial for the first Kite Product ***Confidential Treatment Requested Amgen Contract No. 2014635177 46 directed against such Kite Target, Kite will have the right to terminate this Agreement with respect to such Kite Target […***…] after delivery of written notice to Amgen thereof.
The Parties will cooperate with each other in gaining Patent Right term extension where applicable to Amgen Products and Kite Products and in the case of any disagreement, Amgen would have the final say as to term extension for any Patent Right claiming the composition or method of use of an Amgen Product, and Kite would have the final say as to term extension for any Patent Right claiming the composition or method of use of a Kite Product.
On a Kite Target-by-Kite Target basis, at any time on or prior to the sixtieth (60th) day after the later of (a) delivery of the Final Report to Amgen for the first Kite Product to such Kite Target and (b) filing of the IND for the first Kite Product to such Kite Target and delivery of such IND to Amgen, upon written notice to Kite, Amgen shall have the exclusive right to elect to convert such Kite Target to an Amgen Target.
In the event that any U.S. FDA Approval for KTE-C19 in the US is not completed by […***…] and no Regulatory Approval in the Territory either, the Company may request to swap the KTE-C19 related Licensed Patents and Licensed Data with patents and data related to another Kite Product of Kite available in the Territory, subject to the same terms and conditions under this Agreement, by providing written notice to Kite by […***…].